[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"ETH Zurich\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":387},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,13,0,[8,56,89,121,151,174,197,224,257,285,306,336,360],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":31,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":44,"lastUpdatePostDateStruct":45,"startDateStruct":48,"completionDateStruct":50,"leadSponsor":52,"locationsCount":55},"100602123","icu-background-early-awareness-for-critical-deterioration-100602123",false,"NCT07119411","ICU Background Early Awareness for Critical deterioratiON","ICU Background Early Awareness for Critical deterioratiON (BEACON)","BEACON","Inclusion Criteria:\n\n* admission to intensive care unit\n\nExclusion Criteria:\n\n* age \\\u003C 18 years\n* presence of documented refused general consent form (at database closure)\n* admission for the sole purpose of dying\u002Forgan donation or evaluation of such",true,"ALL","18 Years",{"count":21,"type":22},1962,"ESTIMATED","OBSERVATIONAL","The study will compare ICU sub-units, those with additional support of a clinician awareness system, ICU Beacon, and those receiving the standard of care. The win-ratio composite outcome will be assessed by comparing patients by study group and stratified by APACHE score at admission.",[26,27,28,29,30],"Respiratory Failure","Circulatory Failure","Mortality","Organ Dysfunction","Organ Failure, Multiple",[32,33,34,35,36,37,38,39,40,41,42],"icu","respiratory failure","circulatory failure","early warning system","prevention","prediction","risk prediction","organ failure","multi-organ failure","win-ratio","ICU Beacon","RECRUITING","2026-06-12",{"date":46,"type":47},"2026-06-15","ACTUAL",{"date":49,"type":47},"2025-12-01",{"date":51,"type":22},"2027-11-01",{"name":53,"class":54},"ETH Zurich","OTHER",1,{"id":57,"slug":58,"hasResults":11,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":62,"eligibilityCriteria":63,"healthyVolunteers":11,"sex":64,"minAge":19,"maxAge":65,"enrollmentInfo":66,"targetDuration":4,"studyType":68,"phases":69,"briefSummary":71,"conditions":72,"keywords":74,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},"100626448","iron-absorption-from-ifa-and-mms-supplements-in-kenyan-women-during-the-second-trimester-of-pregnancy-100626448","NCT07435766","Iron Absorption From IFA and MMS Supplements in Kenyan Women During the Second Trimester of Pregnancy","Comparing Iron Absorption From Multiple Micronutrient Supplements and Iron-folate Supplements: a Stable Isotope Study in Kenyan Pregnant Women","PROUD","Inclusion Criteria:\n\n* female\n* pregnant at gestational age 12 (±1) weeks (dated by ultrasound)\n* age 18 to 35 y\n* Hb concentration ≥80 g\u002FL\n* absence of significant inflammation\n* body weight \\\u003C80 kg\n* no major chronic diseases\n* no intake of vitamin and mineral supplements outside of this study in the 1-2 weeks between screening and study start and during the study\n* no blood transfusion, blood donation, or significant blood loss over the past 4 months\n\nExclusion Criteria:\n\n* severe anemia (defined as Hb \\\u003C80 g\u002FL)\n* malaria\n* sickle cell disease (SS and SC)\n* hemoglobin C disease (CC).","FEMALE","35 Years",{"count":67,"type":22},50,"INTERVENTIONAL",[70],"NA","This study evaluates iron absorption from three antenatal supplements, 30 mg MMS, 60 mg MMS, and 60 mg IFA, in 50 pregnant Kenyan women in their second trimester. Using a randomized crossover design and stable iron isotopes, we will compare bioavailability in both fasted and fed states. Additionally, the trial will investigate if daily dosing triggers a hepcidin response that inhibits subsequent absorption, testing whether alternate-day dosing is a more effective strategy for treating iron deficiency.",[73],"Pregnancy",[75,76,77,73,78,79],"Iron Supplements","Dietary Supplements","Iron Deficiency","Stable Iron Isotopes","Iron Absorption","2026-02-20",{"date":82,"type":47},"2026-02-27",{"date":84,"type":22},"2026-03-02",{"date":86,"type":22},"2026-12-31",{"name":53,"class":54},2,{"id":90,"slug":91,"hasResults":11,"nctId":92,"briefTitle":93,"officialTitle":94,"acronym":95,"eligibilityCriteria":96,"healthyVolunteers":17,"sex":18,"minAge":97,"maxAge":98,"enrollmentInfo":99,"targetDuration":4,"studyType":68,"phases":101,"briefSummary":102,"conditions":103,"keywords":108,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":88},"100617182","maximizing-the-benefits-of-iron-in-ready-to-use-therapeutic-foods-for-malnourished-children-in-kenya-100617182","NCT07315295","Maximizing the Benefits of Iron in Ready-to-Use Therapeutic Foods for Malnourished Children in Kenya","Maximizing the Benefits of Iron in Ready-to-use Therapeutic Foods for Malnourished Children in Kenya","SAMI","Inclusion Criteria:\n\nmalnourished children:\n\n* severe acute malnutrition (SAM): WHZ \\\u003C -3.0\n* moderate acute malnutrition (MAM): WHZ \\\u003C -2.0 a\n* treated as outpatients (no acute medical conditions and a positive appetite test)\n\nhealthy children:\n\n\\- healthy: HAZ, WAZ and WHZ = 0\n\nExclusion Criteria (both groups):\n\n* Hemoglobin ≤7 g\u002FdL\n* Presence of acute medical conditions requiring inpatient management","12 Months","54 Months",{"count":100,"type":22},68,[70],"Reports from the Kenya Red Cross Society (KRCS) in Kwale County, southern Kenya, indicate a limited impact of Ready-to-Use Therapeutic Foods (RUTFs) on malnutrition or anemia. The current RUTF formulation may have an excessively high iron content. In severely acutely malnourished (SAM) children, iron cannot be properly absorbed, leading to life-threatening diarrhea. The overall aim of this project is to develop an improved RUTF treatment that addresses acute malnutrition and anemia in children, ensuring both safety and efficacy. Specifically, to assess the impact of malnutrition on fractional iron absorption (FIA) from RUTFs in children, by comparing healthy children to those with acute malnutrition and by tracking changes in FIA in malnourished children over the course of treatment.",[79,104,105,106,107],"Iron Deficiencies","Severly Acutely Malnourished Children","Malnutrition in Children","Anemia",[109,110,111,112],"Ready to use therapeutic foods (RUFTs)","Severe acute malnutrition (SAM)","Stable isotopes","Iron bioavailability","2025-12-18",{"date":115,"type":47},"2026-01-02",{"date":117,"type":22},"2025-12-23",{"date":119,"type":22},"2026-06-30",{"name":53,"class":54},{"id":122,"slug":123,"hasResults":11,"nctId":124,"briefTitle":125,"officialTitle":126,"acronym":127,"eligibilityCriteria":128,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":129,"enrollmentInfo":130,"targetDuration":4,"studyType":68,"phases":132,"briefSummary":133,"conditions":134,"keywords":136,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":55},"100529758","lactobreath-a-study-to-diagnose-lactose-intolerance-using-breath-markers-100529758","NCT06177938","Lactobreath: A Study to Diagnose Lactose Intolerance Using Breath Markers","Lactobreath: A Pilot Study to Diagnose Lactose Intolerance Based on the Exhaled Breath Metabolome","Lactobreath","Inclusion criteria:\n\n* Men and women\n* Swiss and non-Swiss living in the Zurich area (if necessary, beyond Zürich in Switzerland),\n* Ability\u002Fdesire to provide informed consent and partake in the procedures of the study\n* Aged 18-65 years at screening\n* Agreement to refrain from all other treatments and products used for dairy intolerance (e.g., Lactaid® dietary supplements) during study involvement\n* Willing to return for all study visits and complete all study-related procedures, including fasting before and during the intervention\n* Able to understand and provide written informed consent in English and\u002For German.\n\nExclusion criteria:\n\n* Allergic to milk\n* Currently pregnant\n* Currently lactating\n* Cigarette smoking or other use of tobacco or nicotine-containing products within 3 months of screening\n* Diagnosed with any of the following disorders known to be associated with abnormal GI motility: gastroparesis, amyloidosis, neuromuscular diseases (including Parkinson's disease), collagen vascular diseases, alcoholism, uremia, malnutrition, or untreated hypothyroidism\n* History of surgery that alters normal GI tract function, including but not limited to: GI bypass surgery, bariatric surgery, gastric banding, vagotomy, fundoplication, pyloroplasty (N.B. history of uncomplicated abdominal or GI surgeries such as removal of an appendix \\>12 months before screening will not be excluded)\n* Suspected obscure GI bleeding\n* Past or present: organ transplant, chronic pancreatitis, pancreatic insufficiency, symptomatic biliary disease, coeliac disease, diverticular disease, inflammatory bowel disease, strictures (suspected or known), fistulas, or any GI obstruction, gastroparesis, history of gastric bezoar or any other medical condition with symptoms that could confound collection of adverse events\n* Diabetes mellitus\n* Congestive heart failure\n* Human immunodeficiency virus, hepatitis B, or hepatitis C\n* Body mass index \\> 35 kg\u002Fm2\n* Swallowing disorders or dysphagia to food or pills\n* Presence of implantable or portable electro-mechanical medical devices (e.g. pacemakers)\n* Recent bowel preparation for endoscopic or radiologic investigation within 4 weeks of screening (e.g., colonoscopy preparation)\n* Chronic antacid and\u002For proton pump inhibitor use\n* Recent use of systemic antibiotics, defined as use within 2 months prior to screening\n* History of ethanol (alcohol) and\u002For drug abuse in the past 12 months\n* Patients with severe irritable bowel syndrome (IBS) (i.e., IBS Symptom Severity Score \\>400)\n* Dietary restrictions including vegan or vegetarian diet.\n* Any other conditions\u002Fissues noted by the study staff and\u002For Principal Investigator that would impact participation and\u002For protocol compliance.\n* Previous enrollment in another clinical trial within the last 3 months.\n* Results of the screening test showing GI symptoms in response to lactose ingestion and genetic LP.","65 Years",{"count":131,"type":22},120,[70],"Food intolerances affect many people and can cause discomfort and dietary challenges. One common cause is difficulty digesting certain carbohydrates called FODMAPs. Diagnosing food intolerance is often done by excluding and then slowly reintroducing these carbohydrates or using a hydrogen breath test, but these methods have limitations.\n\nTo address these issues, this project uses the breath we exhale to find markers for lactose intolerance as a model for food intolerance diagnosis. Our aim is to identify breath markers for lactose tolerance and intolerance and link them to metabolic traits, including those found in urine. We use a real-time breath analysis method and a special sensor to measure gases in the digestive system, and we also explore genetic factors using saliva samples.\n\nThis project aims to help clinicians better identify patients who should follow low FODMAP diets and provide non-invasive breath tests to predict how patients will respond to these diets. It will also advance the use of breath analysis for personalized nutrition, contributes to the broader field of food intolerance research, and has the potential to benefit millions of individuals worldwide.",[135],"Lactose Intolerance",[137,138,139,140,141,142],"Lactose","Food Biomarker","Metabolome","Food Intolerance","Microbiota","Breath","2025-07-02",{"date":145,"type":47},"2025-07-08",{"date":147,"type":47},"2024-06-24",{"date":149,"type":22},"2025-12",{"name":53,"class":54},{"id":152,"slug":153,"hasResults":11,"nctId":154,"briefTitle":155,"officialTitle":155,"acronym":4,"eligibilityCriteria":156,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":157,"enrollmentInfo":158,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":160,"conditions":161,"keywords":163,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":55},"100577561","natural-course-of-initially-metabolic-healthy-obese-individuals-healthy-obesity-100577561","NCT06799897","Natural Course of Initially Metabolic Healthy Obese Individuals (Healthy Obesity)?","Inclusion Criteria:\n\n* Signed Informed Consent Form\n* Age between 18 and 60 years\n* BMI 30-50 kg\u002Fm2\n* Knowledge of German, which requires sufficient written and allow oral patient education\n\nInclusion criteria for initially healthy group\n\n* Blood pressure \\\u003C 140\u002F90 mmHg\n* Normal glucose metabolism\n\n  * HbA1c \\\u003C 6.5 %\n  * Fasting Glucose \\\u003C 7.0 mmol\u002Fl\n* Normal lipid metabolism\n\n  o LDL-cholesterol \\\u003C 5.0 mmol\u002Fl\n* ≤ 2 of the following metabolic syndrome criteria combined (excluding waist circumference)\n* TG \\> 1.7 mmol\u002Fl\n* HDL-cholesterol \\> 1.0 mmol\u002Fl (male) \u002F \\> 1.3 mmol\u002Fl (female)\n* Fasting glucose ≥ 5.6 mmol\u002Fl\n* BP ≥ 130\u002F85 mmHg\n\nExclusion Criteria:\n\n* Pregnancy\n* Medication and \u002F or pathologies that prevent a safe execution of the fat tissue biopsies\n* History of or planned bariatric operation\n* Medical conditions that prevent examinations and testing (e.g. symptomatic cardiovascular diseases)\n* Active Malignant tumor (\\\u003C2a remission)","60 Years",{"count":159,"type":22},300,"The main goal of this study is to gain a thorough understanding, which specific factors drive the unhealthy sequelae of obesity. Therefore, the investigators want to understand:\n\n1. What distinguishes obese persons without metabolic diseases from those with medical diseases in a cross-sectional comparison?\n2. Which factors drive the conversions from metabolically healthy obesity into a metabolically unhealthy obesity in a longitudinal approach?",[162],"Healthy Obesity, Metabolically",[164,165],"Obesity","Healthy","2025-05-26",{"date":168,"type":47},"2025-05-30",{"date":170,"type":47},"2023-01-18",{"date":172,"type":22},"2026-01-18",{"name":53,"class":54},{"id":175,"slug":176,"hasResults":11,"nctId":177,"briefTitle":178,"officialTitle":179,"acronym":180,"eligibilityCriteria":181,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":182,"enrollmentInfo":183,"targetDuration":4,"studyType":68,"phases":185,"briefSummary":186,"conditions":187,"keywords":189,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":191,"startDateStruct":192,"completionDateStruct":194,"leadSponsor":196,"locationsCount":55},"100526401","mechanisms-of-fasting-induced-reduction-in-energy-expenditure-100526401","NCT06134258","Mechanisms of Fasting Induced Reduction in Energy Expenditure","Mechanisms of Fasting Induced Reduction in Energy Expenditure - FIRE Trial","FIRE","Inclusion Criteria:\n\n* Age: 18 to 40 years\n* Body mass index 18.0 to 27.0 kg\u002Fm²\n* Exclusion Criteria:\n* Chronic conditions necessitating medical treatment (e.g., renal failure, hepatic dysfunction, cardiovascular disease, diabetes mellitus),\n* Known or suspected non-compliance, drug or alcohol abuse,\n* Inability to follow the procedures of the study\n* Participation in another study with investigational drug within the 30 days preceding and during the present study,\n* Previous enrolment into the current study,\n* Enrolment of the investigator, his\u002Fher family members, employees and other dependent persons,\n* Hypothyroidism or hyperthyroidism\n* Pregnant, breastfeeding and menopausal women","40 Years",{"count":184,"type":22},40,[70],"Fasting reduces the energy consumption of the human body. The extent of this adaptation varies significantly between different individuals. The aim of this research project is to investigate how this adaptation of the metabolism is regulated by the body. For this purpose, we will first measure how the so-called basal metabolic rate of the body reacts to a short-term fasting of 24 h in a preliminary study. Those subjects with a particularly pronounced and those subjects with an only slightly pronounced reaction of the basal metabolic rate will be invited to the main study.\n\nHere, in random order (24 h fasting vs. 8 h fasting), the following is compared\n\n* how the basal metabolic rate of the body reacts to the reduced energy intake.\n* how the energy metabolism increases after a test meal\n* what role in particular the thyroid hormones play in this adaptation. In addition, a sample of the subcutaneous adipose tissue is taken in each case and it is examined how the regulation of metabolic processes at the cellular level.",[188],"Fasting",[190],"Thermogenesis",{"date":168,"type":47},{"date":193,"type":47},"2023-11-15",{"date":195,"type":22},"2026-04-18",{"name":53,"class":54},{"id":198,"slug":199,"hasResults":11,"nctId":200,"briefTitle":201,"officialTitle":202,"acronym":203,"eligibilityCriteria":204,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":205,"enrollmentInfo":206,"targetDuration":4,"studyType":68,"phases":208,"briefSummary":210,"conditions":211,"keywords":213,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":217,"lastUpdatePostDateStruct":218,"startDateStruct":220,"completionDateStruct":222,"leadSponsor":223,"locationsCount":88},"100526764","phase-2-pharmacoscopy-guided-clinical-standard-of-care-in-rr-aml-100526764","NCT06138990","Pharmacoscopy-guided Clinical Standard-of-care in r\u002Fr AML","Pharmacoscopy-guided Clinical Standard-of-care in Relapsed\u002FRefractory Acute Myeloid Leukemia, a Randomized Phase-2 Clinical Trial","RAPID-01","Inclusion criteria\n\n* Patient with refractory or relapsed AML according to ELN2022 criteria.\n* Age 18-70 years.\n* Considered to be eligible for intensive chemotherapy.\n* Written informed consent.\n\nExclusion criteria\n\n* Acute promyelocytic leukemia (APL) with PML-RARA or one of the other pathognomonic variant fusion genes\u002Fchromosome translocations.\n* Blast crisis after chronic myeloid leukemia (CML).\n* Considered not eligible for intensive chemotherapy.\n* Condition of the patient does not allow to wait for PCY results (patient requires immediate treatment).\n* PCY not working \u002F patient sample did not pass the QC steps of PCY.\n* Any other serious underlying medical, psychiatric, psychological, familial or geographical condition, which in the judgment of the principal investigator may interfere with the project or affect patient compliance.\n* Legal incompetence or Subjects lacking capacity to provide informed consent.\n* Participation in a clinical trial with an investigational drug within the 30 days preceding and during the present investigation.","70 Years",{"count":207,"type":22},88,[209],"PHASE2","With an overall survival of below 12 months, the outcome of relapsed\u002Frefractory AML (RR AML) is poor, making it a critical challenge to identify effective therapies at this stage. The RAPID-01 trial aims to show for the first time in a randomized and controlled clinical trial that Pharmacoscopy (PCY), a functional precision medicine platform, helps improve clinical standard-of-care treatment selection for patients suffering from relapsed\u002Frefractory AML.",[212],"AML, Adult",[214,215,216],"relapsed \u002F refractory AML","Pharmacoscopy","Functional precision medicine","2025-05-13",{"date":219,"type":47},"2025-05-16",{"date":221,"type":47},"2024-09-02",{"date":119,"type":22},{"name":53,"class":54},{"id":225,"slug":226,"hasResults":11,"nctId":227,"briefTitle":228,"officialTitle":229,"acronym":230,"eligibilityCriteria":231,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":157,"enrollmentInfo":232,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":233,"conditions":234,"keywords":239,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":249,"lastUpdatePostDateStruct":250,"startDateStruct":252,"completionDateStruct":254,"leadSponsor":256,"locationsCount":55},"100581898","response-to-semaglutide-in-non-diabetic-obese-patients-with-varying-degrees-of-insulin-resistance-100581898","NCT06856291","Response to Semaglutide in Non-diabetic Obese Patients With Varying Degrees of Insulin Resistance","Treatment Response to Incretin Mimetics in Non-diabetic Obese Patients With and Without Insulin Resistance (TRIM-IR)","TRIM-IR","Inclusion Criteria:\n\n1. Age between 18 and 60 years\n2. BMI 30 - 40 kg\u002Fm2\n\n   a. Participants must meet the eligibility criteria for coverage under the KVG (Federal Health Insurance Act) and the Specialties List, which include a weight-related comorbidity (arterial hypertension, dyslipidemia) for participants with a BMI of 30- 35 kg\u002Fm2\n3. Planned therapy with semaglutide as a weight loss intervention\n4. No known presence of a diabetic state\n5. Ability to understand and sign a Patient Information and Consent Form\n\nExclusion Criteria:\n\n1. Pregnancy or active breast feeding\n\n   1. Therapy with semaglutide is not approved for use during pregnancy or while breastfeeding, as its safety and efficacy in these conditions have not been established.\n   2. Pregnancy is an exclusion criterion for the planned investigations to avoid placing pregnant individuals under unnecessary physical or psychological stress that could pose risks to both the individual and the fetus.\n2. Medication and\u002For pathologies that prevent the safe execution of the fat tissue biopsies (e.g. allergy towards local anesthetics, disorders of coagulation, treatment with anticoagulants)\n3. Medical conditions that prevent examinations and testing (e.g. epilepsia, symptomatic cardiovascular disease)\n4. History of or planned bariatric surgery\n5. HbA1c ≥ 6.5% as measured by the central laboratory at screening\n6. Fasting plasma-glucose \\>7.0 mmol\u002Fl\n7. History of type 1 or type 2 diabetes mellitus\n8. Treatment with glucose-lowering agent(s) (e.g. Metformin) within 90 days before screening\n9. Treatment with a GLP-1 (glucagon like peptide 1) receptor agonist within 180 days before screening\n10. A self-reported change in body weight \\>5% within 90 days before screening\n11. Active malignancy (\\\u003C2a since remission)\n12. Treatment with any medication for the indication of obesity within the past 90 days before screening\n13. Uncontrolled thyroid disease, defined as thyroid stimulating hormone (TSH) \\> 10 mIU\u002FL or \\\u003C 0.4 mIU\u002FL as measured by the central laboratory at screening",{"count":184,"type":22},"Incretin mimetics are widely used pharmacological treatments for weight loss, known for their high efficacy and favorable safety profile. As the most commonly prescribed drug in this class, semaglutide is effective in both diabetic and non-diabetic individuals. However, treatment responses vary significantly, with non-diabetic individuals typically experiencing better weight loss outcomes. Despite this, up to 10% of non-diabetic individuals show little or no response to treatment, and the reasons for this variability remain unclear.\n\nThe TRIM-IR study aims to investigate the role of insulin resistance (IR) in weight loss outcomes among non-diabetic obese individuals receiving semaglutide. This single-center, observational study will assess the impact of IR on weight loss, body composition, and adipose tissue function during the first 16 weeks of semaglutide therapy. The study will also explore molecular markers of adipose tissue dysfunction, focusing on the transition from dysfunctional to healthy adipose tissue.\n\nThe investigators hypothesize, that individuals with lower IR will experience greater weight loss than those with higher IR, and that the glucose infusion rate (GIR) during hyperinsulinemic euglycemic clamp testing will correlate with weight loss variability. Secondary objectives include comparing changes in fat and lean mass, reductions in visceral fat, and improvements in adipose tissue function before and after 16 weeks of treatment. Exploratory analyses will assess adipocyte subpopulations and their response to insulin sensitivity changes.\n\nA total of 40 participants, equally distributed by gender, will be enrolled to ensure statistical power for detecting clinically relevant differences. The study aims to optimize semaglutide use for personalized obesity treatment and provide insights into the relationship between obesity, insulin resistance, and adipose tissue plasticity, with implications for improving obesity management and cardiovascular health outcomes.",[235,236,237,238],"Obesity and Obesity-related Medical Conditions","Obesity and Overweight","Insulin Sensitivity\u002FResistance","Semaglutide",[240,241,242,243,244,245,246,247,248],"Insulin Resistance","incretin mimetics","semaglutide","weight loss","adipose tissue function","obesity","hyperinsulinemic euglycemic clamp","obesity management","insulin sensitivity","2025-03-24",{"date":251,"type":47},"2025-03-25",{"date":253,"type":47},"2025-03-15",{"date":255,"type":22},"2026-08-31",{"name":53,"class":54},{"id":258,"slug":259,"hasResults":11,"nctId":260,"briefTitle":261,"officialTitle":262,"acronym":263,"eligibilityCriteria":264,"healthyVolunteers":11,"sex":18,"minAge":129,"maxAge":4,"enrollmentInfo":265,"targetDuration":4,"studyType":68,"phases":267,"briefSummary":268,"conditions":269,"keywords":274,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":276,"lastUpdatePostDateStruct":277,"startDateStruct":279,"completionDateStruct":281,"leadSponsor":283,"locationsCount":284},"100539456","restorative-environments-for-gait-therapy-with-vr-100539456","NCT06304077","Restorative Environments for Gait Therapy with VR","Effectiveness of Restorative Landscape Environments in Virtual Reality (VR) Used in Gait Training to Improve Gait Performance and Affect Restoration in Older Adults with Gait Insecurity - a Pilot Randomized Controlled Trial","REGaitVR","Inclusion Criteria:\n\n* age: \\> 65 years\n* german-speaking\n* ability to give informed consent\n* attends gait safety training (usual care)\n* inpatient for a duration of min. 2 weeks in one of the study sites\n* items 7 - 15 of the De Morton Mobility Index (DEMMI): min. 2 points, max. 9 points\n* 3-minute walking distance: \\> 30 m without rest, with or without walking aids, overground walking on flat surface\n\nExclusion Criteria:\n\n* epilepsy\n* Partial weight bearing or conservatively or surgically treated billing with weight bearing as determined by symptoms\n* Severe hearing impairment (if not corrected with hearing aid)\n* Injuries to the eyes, face, or neck that prevent comfortable use of VR glasses.",{"count":266,"type":22},84,[70],"The aim of our study is to investigate the effects of landscapes during gait therapy. The investigators will evaluate the impacts of restorative landscapes as they occur in urban, rural and forest environments. Older people will experience those landscapes using virtual reality (VR) goggles during their gait training. The investigators expect the landscapes to have an effect on the following three aspects: (1) stress reduction, (2) restoration of attention and (3) change in gait parameters. For this purpose, volunteers who are currently inpatient in one of our study centers and already participating in gait therapy will be assigned to a group. The control group will receive the standard therapy. The participants of the intervention groups will receive five additional VR training sessions to the standard therapy. In these sessions, the participants will walk through urban, rural and forest landscapes and perform balance improvement exercises. The five training sessions will take place within ten days. Allocation to the control or intervention groups and their landscapes is random. At the start and end of participation, tests defining stress levels and gait parameters are carried out so that comparisons can be made between before and after treatment. The goal of the study is to find out which type of landscape supports restoration and can therefore contribute to greater gait stability. The investigators expect that improved gait stability will be promoted by stress reduction and increased attention induced by the virtual environments. The investigators are investigating the consequences of repeated application of virtual landscapes and the relationship between the effect of the landscape and the preferences and habits of the study participants.",[270,271,272,273],"Gait Analysis","Virtual Reality","Attention","Stress",[275],"virtual reality (VR) based gait therapy","2025-03-06",{"date":278,"type":47},"2025-03-11",{"date":280,"type":47},"2024-04-23",{"date":282,"type":22},"2025-08-31",{"name":53,"class":54},3,{"id":286,"slug":287,"hasResults":11,"nctId":288,"briefTitle":289,"officialTitle":289,"acronym":4,"eligibilityCriteria":290,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":291,"targetDuration":4,"studyType":68,"phases":292,"briefSummary":293,"conditions":294,"keywords":4,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":298,"lastUpdatePostDateStruct":299,"startDateStruct":301,"completionDateStruct":303,"leadSponsor":305,"locationsCount":55},"100447032","neurofeedback-using-implanted-deep-brain-stimulation-electrodes-100447032","NCT05101161","Neurofeedback Using Implanted Deep Brain Stimulation Electrodes","Inclusion Criteria:\n\npatients undergoing clinically indicated implantation of a Percept™ PC neurostimulator, age ≥ 18 years as well as planned hospitalisation of ≥ 3 days after operation\n\nExclusion Criteria:\n\nminimal prognosticated survival of less than 1 year, reduced state of consciousness (i. e. Glasgow Coma Scale \\\u003C 15), inability to communicate (in terms of hearing, seeing, speaking and understanding), other significant concomitant diseases (e. g. cardiovascular disease, infectious disease, isolation), inability to follow procedures, insufficient knowledge of project language, inability to give consent and unlikeliness to follow protocol.",{"count":67,"type":22},[70],"Deep brain stimulation (DBS) has become a gold-standard symptomatic treatment option for Parkinson's disease (PD) and is also explored for a variety of other neurological disorders. The implantation of electrodes into deep brain areas has not only enabled the application of electrical stimuli, but has also provided researchers and clinicians with an unprecedented window to investigate aberrant neuronal activity right at the core of pathological brain circuits. Local field potentials (LFP) have already been readily investigated through externalised DBS electrode wires prior to internalisation and connection to an implantable neurostimulator. In the case of PD, motor symptoms have been evidenced to correlate with exaggerated beta oscillatory activity (13-35 Hz) in the LFP recorded from the subthalamic nucleus (STN). Firstly, beta activity recorded in the STN at rest in patients withdrawn from their medication has been correlated with the Unified Parkinson's Disease Rating Scale (UPDRS) across patients. Secondly, a reduction of signal power in the beta-band was correlated with clinical improvements of motor symptoms. Thirdly, the two main therapeutic strategies, the administration of L-Dopa, and high-frequency DBS both lead to a suppression of beta-synchronicity in the STN. Furthermore, beta-oscillations show fast and movement-dependent modulation over time and can serve as a biomarker and feedback signal to control the delivery of DBS. The investigators recently implemented deep brain electrical neurofeedback to provide real-time visual neurofeedback of pathological STN oscillations through externalised DBS electrodes and showed that PD patients were able to volitionally control and reduce subthalamic activity within a single 1 hour session. Moreover, neurofeedback-learnt strategies accelerated movements and could be retained in the short- and mid-term. Only recently, a newly developed neurostimulator, the Percept™ PC (Medtronic Neurological Division, Minneapolis, MN, USA), has been clinically approved, which can not only apply electrical impulses, but also enable the measurement and transmission of brain activity. This neurostimulator is now the first choice for implantations at the University Hospital Zurich and is used for a variety of neurological disorders. The investigators' goal is to investigate whether neurofeedback through a fully implanted deep brain stimulation device is possible and can lead to a better control of pathological oscillations as well as symptom mitigation. Having shown that endogenous control over deep brain oscillations is possible, the investigators will also test this novel therapeutic approach for pathologies other than PD that are also treated with DBS. Neurofeedback using implanted DBS electrodes will have the advantage of enabling longer and multiple-day training sessions, which the investigators hypothesise to have a larger impact on control over pathological deep brain oscillations and neurological symptoms, as such a fully implanted neurofeedback system no longer requires the externalisation of DBS wires and is as such no longer limited to the first two days after electrode implantation. All in all, the investigators will not exceed a total streaming time of 7 hours per patients (7 d of battery time), which the investigators deem justifiable with respect to a battery life of \\> 5 years. This proposed research is highly significant as it will help our understanding of various neurological diseases that are highly prevalent in society (PD being, for instance, the second most common neurodegenerative disorder after Alzheimer's disease) and might culminate in novel, endogenous treatment strategies. The overall risk for patients is minimal to non-existent, as stimulation parameters are unaffected and the intended changes in brain activity are self-induced while DBS stimulation is off.",[295,296,297],"Parkinson Disease","Epilepsy","Essential Tremor","2025-02-25",{"date":300,"type":47},"2025-02-27",{"date":302,"type":47},"2021-09-23",{"date":304,"type":22},"2026-09-23",{"name":53,"class":54},{"id":307,"slug":308,"hasResults":11,"nctId":309,"briefTitle":310,"officialTitle":311,"acronym":312,"eligibilityCriteria":313,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":314,"enrollmentInfo":315,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":317,"conditions":318,"keywords":321,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":327,"lastUpdatePostDateStruct":328,"startDateStruct":330,"completionDateStruct":332,"leadSponsor":334,"locationsCount":335},"100519518","unveiling-physiological-and-psychosocial-pain-components-with-an-artificial-intelligence-based-telemonitoring-tool-100519518","NCT06044584","Unveiling Physiological and Psychosocial Pain Components with an Artificial Intelligence Based Telemonitoring Tool","Unveiling Physiological and Psychosocial Pain Components with an Artificial Intelligence Based Telemonitoring Tool (pAIn-sense)","pAIn-sense","Inclusion Criteria:\n\n* Ongoing nociceptive pain after an injury or Neuropathic pain (acute or chronic)\n* Familiar with using electronic devices\n\nExclusion Criteria:\n\n* Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc.\n* Unable or not willing to give informed consent","80 Years",{"count":316,"type":22},150,"The pAIn-sense study aims to revolutionize the monitoring and treatment of chronic pain, a major health concern that significantly impacts psychological well-being and quality of life. Traditional approaches to pain management face challenges like unspecific drug use and high healthcare costs, and they often leave patients dissatisfied. PAIn-sense aims at comprehensively understanding pain from both physical and emotional perspectives. To accomplish this, the study will employ advanced Artificial Intelligence (AI) techniques and wearable sensing technology. The study aims to monitor patients continuously, during both day and night activities, to gather a multidimensional set of data on their physiological, psychosocial, and pain conditions.",[319,320],"Nociceptive Pain","Neuropathic Pain",[322,323,324,325,326],"Pain","Telemonitoring","Artificial Intelligence","Physiological signals","Psychosocial","2025-01-17",{"date":329,"type":47},"2025-01-20",{"date":331,"type":47},"2023-09-29",{"date":333,"type":22},"2028-12-31",{"name":53,"class":54},4,{"id":337,"slug":338,"hasResults":11,"nctId":339,"briefTitle":340,"officialTitle":340,"acronym":341,"eligibilityCriteria":342,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":314,"enrollmentInfo":343,"targetDuration":4,"studyType":68,"phases":344,"briefSummary":345,"conditions":346,"keywords":4,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":352,"lastUpdatePostDateStruct":353,"startDateStruct":355,"completionDateStruct":357,"leadSponsor":359,"locationsCount":55},"100476429","multisensory-stimulation-to-target-sensory-loss-and-chronic-pain-in-neuropathic-patients-100476429","NCT05483816","MultiSENSory Stimulation to TArgeT Sensory Loss and ChronIc Pain in NeurOpathic PatieNts","SENSATION","for healthy:\n\n* Inclusion:\n\n  * Age 18-80\n  * Visual acuity\\>6 on Snellen visual acuity chart\n* Exclusion:\n\n  * Pregnancy\n  * Cognitive deficits (Mini Mental State Examination\\<23)\n  * Cyber-sickness\n  * Prior or current psychological diseases\n  * Pacemakers\n  * Epilepsy\n  * Claustrophobia\n  * Other MRI contraindications\n  * Unhealed fractures\n  * Unhealed wounds\n  * Cancerous growth in proximity to feet\n  * Swollen, infected or inflamed areas on feet or skin eruptions on feet such as phlebitis, thrombophlebitis or varicose veins\n\nfor patients:\n\n* Inclusion:\n\n  * Age 18-80\n  * Visual acuity\\>6 on Snellen visual acuity chart\n  * Diagnosis of peripheral neuropathy\n  * Pain in lower limbs\\>=3 cm on VAS scale\n* Exclusion:\n\n  * Pregnancy\n  * Relevant comorbidities that would affect the outcomes of the study (by judgement of physicians)\n  * Ulcers\n  * Cognitive deficits (Mini Mental State Examination\\<23)\n  * Cyber-sickness\n  * Prior or current psychological diseases\n  * Pacemakers\n  * Epilepsy\n  * Claustrophobia\n  * Other MRI contraindications\n  * Unhealed fractures\n  * Unhealed wounds\n  * Cancerous growth in proximity to feet",{"count":184,"type":22},[70],"Neuropathy is a costly and disabling health issue, which consists of a degeneration of the peripheral nerves. Even though the causes may be different, such as diabetes or amputation, the consequences for neuropathic patients are multiple and extremely debilitating. Among the alarming symptoms it implicates, chronic pain and sensory loss are among the most severe ones. Because of the loss of sensations, patients are forced to have an altered gait strategy, an impaired balance and a fivefold increased risk of falling. Furthermore, since they lose sensations and feel numbness in their extremity, they are discouraged in walking, hence leading to a sedentary lifestyle. All of this is worsened by the development of neuropathic pain, which has a high comorbidity with psychological issues, such as depression and anxiety.\n\nToday, proper treatments for neuropathic pain that exclude pharmacological solutions are still missing. This is due to the complexity of the neurobiological mechanisms underlying the origin of neuropathy, the multifaceted physical and psychological nature of pain and the lack of reliable biomarkers.\n\nThe aim of this project is to tackle the major problems connected to neuropathy thanks to non-invasive stimulation of the peripheral nervous system. The system is composed of an insole with pressure sensors that captures in real time the force exerted by the subject on the foot and couples this information with parameters of electrical stimulation. Thanks to optimal electrode placement and intensity modulation, subjects are able to perceive in real-time in a somatotopic manner (i.e., under their foot) how they are walking. The aim now is twofold: first the investigators want to couple this stimulation with Virtual Reality (VR) to develop a neuroadaptive non-invasive brain computer interface (BCI) to treat pain and secondly the investigators want to measure through fMRI scans whether the use of the sensory feedback system allows any beneficial plastic changes in the brain. Finally, the investigators want to measure through fMRI scans whether the use of the sensory feedback system allows any beneficial plastic changes in the brain.",[347,348,349,350,351],"Neuropathy","Neuropathy, Painful","Sensory Neuropathy","Diabetic Neuropathies","Amputation","2024-11-14",{"date":354,"type":47},"2024-11-18",{"date":356,"type":47},"2022-06-30",{"date":358,"type":22},"2028-02-28",{"name":53,"class":54},{"id":361,"slug":362,"hasResults":11,"nctId":363,"briefTitle":364,"officialTitle":365,"acronym":4,"eligibilityCriteria":366,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":182,"enrollmentInfo":367,"targetDuration":4,"studyType":68,"phases":369,"briefSummary":370,"conditions":371,"keywords":374,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":379,"lastUpdatePostDateStruct":380,"startDateStruct":382,"completionDateStruct":384,"leadSponsor":386,"locationsCount":55},"100551816","pilot-trial-bioavailability-animal-vs-plant-protein-drink-100551816","NCT06465004","Pilot Trial: Bioavailability Animal vs. Plant Protein Drink","Exploratory Pilot Trial Assessing the Immediate Impact of Animal-based and Plant-based Protein Drinks on Blood Parameters","Inclusion criteria\n\n* Gender: male and female\n* Age: 18-40 years\n* Signed written informed consent\n\nExclusion criteria\n\n* Smoking history\n* Cardiovascular diseases\n* BMI \\> 35 kg\u002Fm2\n* Caffeine consumption \\\u003C 1 day before the study participation\n* Allergies: Soy, Peas, Milk, Lactose, Fructose\n* High intensity exercise \\\u003C2 days before study participation",{"count":368,"type":22},12,[70],"A pilot study is being conducted to compare a new plant-based protein drink to commercially available animal-based protein drinks. The goal is to assess if the plant-based drink delivers amino acids to the bloodstream as effectively as the animal-based drinks, potentially offering a viable option for those on plant-based diets.\n\nThe study will involve approximately 12 healthy adults aged 18-40. Each participant will try all three drinks (the new plant-based drink, a commercial animal-based drink, and another animal-based recipe) on separate days in a randomized order. Before and after (30, 60, and 90 minutes) consuming each drink, a small blood sample will be drawn to measure amino acid levels (leucine).\n\nBy comparing the results, the investigators hope to determine if the plant-based drink can match the effectiveness of animal-based protein drinks in delivering essential nutrients. This research could contribute to the development of sustainable and nutritious plant-based protein alternatives.",[372,373],"Nutrition, Healthy","Leucine Sensitivity",[375,376,377,378],"Leucin","Plant-based","Animal-based","Bioavailability","2024-06-18",{"date":381,"type":47},"2024-06-21",{"date":383,"type":47},"2024-06-08",{"date":385,"type":22},"2024-08-30",{"name":53,"class":54},""]